Introduction
Heart failure (HF) is a clinical syndrome resulting from an abnormal cardiac structure or function which impairs the heart's ability to meet the oxygen and nutrient requirements of metabolizing tissues, and leads to pulmonary venous congestion.
1,2 'Backward' failure may further lead to pulmonary venous hypertension, right ventricular (RV) dysfunction, renal venous hypertension and renal dysfunction. Bedside assessment of venous congestion is important for the classification of acutely decompensated patients into 'wet' vs. 'dry' phenotypes, which then guides clinical management, e.g. aggressive diuresis in 'wet' patients. Conversely, under-recognition of the extent of venous congestion can lead to inadequate diuresis and higher rehospitalization rates. The assessment of venous congestion is particularly challenging in patients with HF and preserved ejection fraction (HFpEF), who are frequently obese with age-related non-cardiac co-morbidities.
We aimed to compare the extent of venous congestion, RV and renal dysfunction at acute presentation in patients with HFpEF vs. HF with reduced ejection fraction (HFrEF) and non-cardiac dyspnoea using echocardiographic and circulating biomarkers.
Methods

Patient population
We analysed the data of patients included in MEDIA-DHF (The Metabolic Road to Diastolic Heart Failure: Diastolic Heart Failure study; NCT02446327). MEDIA-DHF enrolled patients with acute dyspnoea of non-cardiac origin, acutely decompensated heart failure (ADHF) and chronic HF. For this specific substudy, a database was constructed between February 2011 and April 2014, including eligible patients admitted for acute dyspnoea of cardiac or non-cardiac origin as the main symptom at the emergency departments of Hôpital Lariboisière (Paris) and Hôpital Universitaire Jean Minjoz (Besançon), both in France. The aim of this study was to characterize acute HFpEF, HFrEF and acute dyspnoea of non-cardiac origin, with special emphasis on congestion, RV and kidney dysfunction at admission. Inclusion criteria were age > 18 years and acute dyspnoea. Exclusion criteria were acute coronary syndromes, inotropic support within the last 2 h before inclusion, systolic blood pressure persistently below 90 mmHg, severe aortic or mitral valvulopathy, pneumothorax, recent surgery or trauma (< 3 months), severe or end-stage renal impairment (clearance <30 mL/min or dialysis), chronic liver disease, chronic infectious (bacterial of viral) disease, cerebrovascular disease or stroke in the last 3 months, any malignant concomitant diseases or a malignant disease in the last 5 years, systemic inflammatory diseases, such as autoimmune diseases, connective tissue diseases or collagenoses, pregnancy. The adjudicated final diagnosis (ADHF or non-cardiac dyspnoea) was performed independently by two cardiologists not in charge of the patients, yet with unlimited access to clinical, biochemical and imaging materials obtained in the emergency departments, intensive or cardiac care units and during the remainder of the hospitalization. When the two experts disagreed regarding the final diagnosis, a third physician adjudicated the final diagnosis. 3 The study protocol complied with 
Echocardiography
Echocardiographic measurements of chamber and vessel dimensions and cardiac systolic and diastolic functions were obtained according to the guidelines by cardiologists experienced in echocardiographic measurements (R.P. and M.F.S.) within 4 h of presentation for dyspnoea in the emergency department, using standard acoustic windows on a Philips CX50 or iE33 ultrasound system. 4 We aimed for a comprehensive assessment of echocardiographic parameters of congestion, systolic and diastolic ventricular function in every patient. When clinical presentation interfered with appropriate cardiac imaging, assessment of systolic function was prioritized over diastolic function and left ventricular filling pressures, which were preferred over additional echocardiographic parameters of congestion. Ventriculo-arterial coupling was calculated as the quotient of end-systolic volume and stroke volume. 5 Investigators involved in image acquisition were blinded to obtained natriuretic peptide levels and were not involved in further statistical analysis of the data. ADHF patients were divided into three subgroups based on their left ventricular ejection fraction (LVEF) on admission: reduced LVEF <40% (HFrEF); mid-range LVEF between 40 and 49% (HFmrEF); preserved LVEF >50% (HFpEF). 1
Biomarkers
During initial presentation in the emergency department and at discharge, blood samples were collected in plastic tubes containing ethylenediaminetetra-acetic acid. Aliquots of plasma samples were stored at −80 ∘ C for further analysis. Apart from routinely used markers of kidney and liver function, several plasma biomarkers reflecting different pathophysiological pathways in HF were assessed: brain natriuretic peptide (BNP; Abbott), mid-regional pro-atrial natriuretic peptide (MR-proANP; BRAHMS AG -ThermoFisher), high sensitive troponin I (hsTnI; Roche Diagnostics), cluster of differentiation 62E and 146 (CD62E, soluble CD146 or sCD146; Biocytex), mid-regional pro-adrenomedullin (MR-proADM; ThermoFisher Diagnostics), soluble ST2 (Critical Diagnostics), galectin 3 (Abbott), C-reactive protein (CRP; Siemens), procalcitonin (BRAHMS AG -ThermoFisher), intercellular adhesion molecule 3 (ICAM3; Abcam), cystatine C (Abbott), neutrophil gelatinase associated lipocalin (NGAL; Abbott).
Follow-up and outcome
After discharge, patient outcome was followed for 1 year, with structured telephone calls at 3, 6 and 12 months after admission. An adverse event was defined as death or cardiovascular rehospitalization, whichever came first. Death occurring on the first day of (re)hospitalization was defined as death rather than (re)hospitalization.
Statistical analysis
Continuous variables are expressed as means with standard deviations (SD) when normally distributed or as medians with interquartile ranges (IQR) when not normally distributed. Normality was assessed by the Shapiro-Wilk test. Categorical variables are presented as numbers and percentages. Groups were compared using one-way analysis of variance (ANOVA) or non-parametric alternatives as appropriate. Subsequent pairwise comparisons were (7) 0.001 Peripheral artery disease, n (%) COPD, n (%) 8 (8) 8 (8) 3 (7) 7 (16) 1.000 0.236
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31 ( ACE, angiotensin converting enzyme; ADHF, acutely decompensated heart failure; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention. ADHF, acutely decompensated heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IVC, inferior vena cava; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; MAPSE, mitral annular peak systolic excursion; PAP, pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.
performed using Bonferroni correction for multiple comparisons.
A P-value of <0.05 was considered statistically significant. Statistical analyses were performed using STATA 14.1 (StataCorp, College Station, TX, USA) and GraphPad Prism 6.0 h (GraphPad Software, La Jolla, CA, USA).
Results
Patient characteristics at admission
In total, 146 patients were prospectively included in the MEDIA cohort. Table 1 presents baseline characteristics of groups separated according to the aetiology of acute dyspnoea: ADHF vs. non-cardiac dyspnoea, and within ADHF: HFpEF (LVEF >50%, n = 38) vs. HFrEF (LVEF <40%, n = 41). Among ADHF patients, HFpEF patients were nearly two decades older [79 years (70-87)] than HFrEF patients [63 years (56-77); P = 0.003). Most HFpEF patients were women (66%), whereas 78% of HFrEF patients were men (P < 0.001). Whereas most clinical signs of congestion (jugular vein distension, peripheral oedema, pulmonary rales) were significantly different between ADHF and non-cardiac dyspnoea, the clinical presentation of HFpEF and HFrEF was comparable. Yet, at admission, oxygen saturation (SaO 2 ) and heart rate were lower in HFpEF patients compared with HFrEF patients [SaO 2 : 91 ± 6% vs. 95 ± 4%, P = 0.006; heart rate: 75 b.p.m. After 1 year of follow-up, death or rehospitalization occurred in 16% of patients with dyspnoea of non-cardiac origin while markedly higher (52%; P = 0.001) in patients admitted for ADHF, including 47% (18 out of 38 patients) for HFpEF and 51% (21 out of 41 patients) for HFrEF (P = 0.227; Table 1 and supplementary material online, Figure S1 ).
When comparing HFpEF with HFmrEF (LVEF 40-49%, n = 22), 1 there was no difference in clinical characteristics nor in the rate of death or rehospitalization (data not shown).
Echocardiographic parameters at admission (Table 2 and Figure 1)
Left and right ventricular function
In our MEDIA-DHF cohort, parameters of left and right ventricular function were both altered in ADHF patients compared to non-cardiac dyspnoea patients ( Figure 1A) . Notably, tricuspid annular plane systolic excursion (TAPSE) was on average 17 mm in ADHF (IQR: 14-20 mm) and 24 mm (IQR: 20-28 mm) in non-cardiac dyspnoea patients (P = 0.001).
Concerning ADHF patients, HFpEF manifested higher LVEF (P < 0.001) and left ventricular mass (P = 0.042), yet lower left ventricular end-diastolic diameter (P < 0.001) and left ventricular end-systolic diameter (P < 0.001) compared with HFrEF. However, RV function was similarly altered in HFpEF and HFrEF, with a ADHF, acutely decompensated heart failure; BNP, brain natriuretic peptide; CD62E, cluster of differentiation 62E; sCD146, soluble cluster of differentiation 146; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ICAM3, intercellular adhesion molecule 3; MDRD, Modification of Diet in Renal Disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hsTnI, high sensitive troponin I; ICAM3, intercellular adhesion molecule 3; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NGAL, neutrophil gelatinase associated lipocalin.
comparable percentage of HFpEF and HFrEF patients having reduced (TAPSE <15 mm in 20% and 18% of patients, respectively; P = 1.000) or severely reduced RV longitudinal function (TAPSE <10 mm in 10% and 4% of patients, respectively; P = 0.563).
Echocardiographic parameters of haemodynamic congestion
At admission, ADHF showed higher left and right atrial areas, E/e', pulmonary artery systolic pressure, IVC diameter at rest and lower IVC variability compared to non-cardiac dyspnoea patients ( Figure 1B) . Among ADHF patients, HFpEF and HFrEF had comparable echocardiographic signs of haemodynamic congestion (all P > 0.05).
Circulating biological markers at admission (Table 3)
Markers of inflammation and fibrosis ADHF patients had increased levels of markers of inflammation and fibrosis, as evidenced by increased soluble ST2 and ICAM3 compared to non-cardiac dyspnoea patients (P = 0.001 and 0.042, respectively). However, levels of CRP, galectin 3, procalcitonin and CD62E were similar in ADHF and non-cardiac dyspnoea groups. No difference in any of these biomarkers could be seen between HFpEF and HFrEF.
. 
Markers of cardiovascular stress and congestion
BNP, MR-proANP, hsTnI and sCD146 all discriminated well between our ADHF and non-cardiac dyspnoea groups (P = 0.001 for all comparisons; Table 3 ). 
Correlation between echocardiographic and biochemical markers of congestion
Comparison of echocardiographic parameters of cardiac (right and left atrial) or peripheral (IVC) congestion and BNP, hsTnI or MR-proADM, showed no correlation. In contrast, circulating levels of MR-proANP and sCD146 were tightly associated with left and right atrial areas, IVC diameter at end expiration (Figure 2a) , IVC variability, E/e' and pulmonary artery systolic pressure (see supplementary material online, Table S1 ). Figure 2b shows that the combination of elevated MR-proANP and sCD146 at admission for acute dyspnoea was associated with cardiac and peripheral congestion. However, these markers were similarly altered in HFpEF and HFrEF patients.
In all ADHF patients combined, Figure 3 shows that eGFR was not correlated with cardiac index (r = 0.096 and P = 0.5939), nor right atrial area (r = −0.332 and P = 0.0734) yet with IVC diameter (r = −0.291 and P = 0.0241).
The supplementary material online, Figure S2 shows that in both HFpEF and HFrEF, eGFR did not correlate with cardiac index nor TAPSE. In contrast, right atrial area and IVC diameter at rest associated with eGFR in HFrEF, yet not in HFpEF patients.
Discussion
The MEDIA-DHF study showed that acute HFpEF and HFrEF present with comparable echocardiographic and biomarker (MR-proANP, sCD146) signs of venous congestion, RV and renal dysfunction, in spite of differences in left ventricular wall stress (BNP). This suggests that patients with acute HFpEF may benefit from aggressive decongestion with diuretics as much as patients . with acute HFrEF, and that these therapeutic efforts should not be guided by presenting BNP levels. Consistent with prior studies, 6 -11 our study confirmed that acute HFpEF predominantly affects old hypertensive women who present with acute dyspnoea and hypoxaemia. We further showed, using imaging and circulating biomarkers, that acute HFpEF and acute HFrEF shared similar features: (i) increased natriuretic peptides, (ii) increased pulmonary pressure, (iii) altered RV function, (iv) enlarged IVC, (v) altered renal function, and (vi) poor outcomes. Altogether, those data demonstrated that acute HFpEF represents bona fide ADHF as much as acute HFrEF. Our data are in line with findings in the chronic setting, in which haemodynamic congestion and RV dysfunction have been similarly reported in chronic HFpEF and HFrEF, and associated with worse outcomes.
12 -14
Filling pressures are frequently assessed by echocardiography to substantiate an equivocal clinical diagnosis of congestion and to guide titration of diuretic therapy. 15, 16 In our study population, non-cardiac dyspnoea patients had significantly lower E/e' values compared with ADHF patients. In contrast, filling pressures could not differentiate between acute HFrEF and HFpEF. Importantly, this straightforward measurement becomes unreliable with incorrect sample volume placement and rather common clinical scenarios such as sinus tachycardia, atrial fibrillation, mitral annular calcification, severe mitral regurgitation, ventricular dyssynchrony and regional wall motion abnormalities. 17 We hypothesize that in an all-comer, real world situation, the discriminatory potential of filling pressures between cardiac and non-cardiac dyspnoea is likely worse than reported in our study, given our non-inclusion . of patients with acute coronary syndromes and severe aortic or mitral valvuloplasty, as well as our reliance on experienced cardiologists for imaging.
Our study confirmed that all circulating biomarkers of congestion were similarly high in both acute HFpEF and HFrEF, with the exception of a much lower level of BNP in acute HFpEF compared to HFrEF. 6, 18 A higher BNP may be expected in acute HFrEF vs. HFpEF given the greater left ventricular wall stress, the stimulus for BNP release, in an eccentrically remodeled heart in HFrEF. Importantly, BNP levels (marker of left ventricular wall stress) did not correlate with echocardiographic markers of venous congestion, whereas MR-proANP (marker of cardiac congestion) and sCD146 (marker of venous congestion) did. MR-proANP is the stable prohormone fragment of proANP, mainly released by the atrial myocardium in response to increased filling pressures.
1,19,20
Soluble CD146 is expressed on the endothelial cell surface and is released in the bloodstream in response to venous stretch or stress in acute HF patients 21 and in chronic HF patients. 22 Our study showed a relationship between MR-proANP and sCD146 and echocardiographic signs of venous congestion in acute dyspnoeic patients. Based on these results, we hypothesize that in ADHF, BNP, while a good marker of HF vs. non-cardiac dyspnoea, may not accurately reflect the degree of venous congestion and may therefore not be the ideal marker to guide decongestion therapy. In contrast, MR-proANP and sCD146 could hold potential to be used as markers in ADHF for venous congestion, a hypothesis worthy of testing in future prospective studies. Admittedly, another mechanism at play in acute HF, not necessarily pertaining to venous congestion, might account for our observed associations.
MEDIA-DHF also showed that kidney dysfunction was associated with echocardiographic parameters of right-sided congestion rather than RV and LV systolic performance in ADHF patients. Importantly, further subdivision of ADHF in HFpEF and HFrEF revealed a divergent impact of haemodynamic congestion on kidney dysfunction. Whereas the latter and right-sided congestion correlated in HFrEF, this relationship was not present in HFpEF. We hypothesize that this finding indicates that different pathophysiologic mechanisms may being responsible for kidney dysfunction in acute HFpEF and HFrEF. Whereas haemodynamic congestion might be the main determinant of kidney dysfunction in acute HFrEF, endothelial dysfunction could be the main driver of kidney dysfunction in acute HFpEF. be assessed by the combination of elevated MR-proANP and sCD146. In the future, those biomarkers might help to adjust initial decongestive therapies, in case echocardiography is not immediately available. Our study also showed that kidney dysfunction may have different mechanisms in HFrEF and HFpEF. This finding may support the combined use of decongestive and renoprotective therapies as optimal standard therapy in all ADHF patients. Our study has its limitations. First, included patients were derived from two tertiary care facilities only. Whereas the advantages of this approach certainly were uniform sample handling, analyses and data management, this approach might have introduced bias, in particular deviation of the studied sample from the general population. However, the clinical characteristics at admission of HFpEF, HFrEF and non-cardiac dyspnoea patients are reminiscent of clinical practice and earlier studies, 24, 25 making us confident about the generalizability and reliability of our results. Secondly, we included 146 patients in our cohort; yet, we felt this provided enough power to detect statistical significance and clinical relevance between (sub)group differences, while avoiding statistically significant, although clinically irrelevant, findings. Nonetheless, future research should validate our findings in a medium-sized or large-sized independent set of patients in a multicentre study.
In conclusion, under acute conditions, HFpEF and HFrEF present in a comparable state of venous congestion, with similarly altered RV and kidney function, despite lower BNP in HFpEF. These findings carry implications for decongestive therapy in ADHF regardless of EF.
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